Burden of acquisition-related costs and upfront costs for new orders
First written in FY2017. 16 of 20 entries say "Materialised", first in FY2017. Latest entry: FY2025.
No other company in this theme has enough history to compare yet.
- FY2025MaterialisedAnnual report
「Profit was weighed down by upfront costs aimed at future growth, including production ramp-up costs for new mobility products in the industrial materials business and impairment losses on existing facilities to expand production capacity for CDMO services for over-the-counter drugs.」
Upfront costs, including production ramp-up costs for new mobility products, impairment losses on facilities for over-the-counter drug CDMO operations and acquisition-related expenses, actually weighed on current net income. - FY2025-H1MaterialisedAnnual report
「Against this backdrop of demand, net sales increased year on year, but operating profit decreased year on year due to upfront costs related to new products for the mobility sector, among other factors.」
Upfront costs related to new products for the mobility sector were incurred in the industrial materials business. Although sales increased, operating profit declined 19.6% year on year. - FY2024MaterialisedAnnual report
「¥55 million was recorded in selling, general and administrative expenses as acquisition-related costs.」
The company recorded ¥55 million in acquisition-related costs associated with the acquisition of Cathtek. It also recorded ¥86 million in acquisition-related costs for Isometric during the period, resulting in acquisition-related expenses. - FY2024-Q1MaterialisedAnnual report
「Acquisition-related costs for the business combination were ¥114 million, of which ¥28 million was recorded in selling, general and administrative expenses in the previous fiscal year and ¥86 million in the six months ended the first quarter.」
The ¥86 million in acquisition-related costs associated with Isometric’s business combination was recorded during the quarter, and the burden of acquisition-related expenses was actually incurred. - FY2022-Q3MitigatedAnnual report
「Loss on factory closures 10 These relate to the integration of European production sites at a consolidated subsidiary in the “Medical Technology” segment.」
The loss on factory closures associated with the integration of Medical Technology’s European production sites was ¥10 million, down from ¥23 million in the same period of the previous year. - FY2022-Q2MitigatedAnnual report
「Loss on factory closures 6 These relate to the integration of European production sites at a consolidated subsidiary in the “Medical Technology” segment.」
The loss on factory closures associated with the integration of Medical Technology’s European production sites was ¥6 million, down from ¥18 million in the same period of the previous year. However, integration-related costs continue to be incurred. - FY2021-Q3MitigatedAnnual report
「Loss on factory closures 23 These relate to the integration of European production sites at a consolidated subsidiary in the “Medical Technology” segment.」
The loss on factory closures associated with the integration of Medical Technology’s European production sites was ¥23 million, down from ¥70 million in the same period of the previous year. However, integration-related costs continue to be incurred. - FY2021-Q2MaterialisedAnnual report
「Loss on factory closures 18 These relate to the integration of European production sites at a consolidated subsidiary in the “Medical Technology” segment.」
The company recorded an ¥18 million loss on factory closures associated with the integration of Medical Technology’s European production sites, and costs related to the acquisition and site integration remain ongoing. - FY2020-Q3MaterialisedAnnual report
「Business structure improvement expenses 2,051 Loss on factory closures 70」
The company recorded ¥2,051 million in business structure improvement expenses, including costs related to voluntary retirements under the profitability enhancement measures, and ¥70 million in losses on factory closures, so the burden of one-off expenses continued. - FY2020-Q2MaterialisedAnnual report
「In the six months ended the second quarter, the company recorded ¥2,042 million in business structure improvement expenses and ¥98 million in losses on factory closures as other expenses. The business structure improvement expenses consisted of special additional payments and outplacement support program costs arising from the solicitation of voluntary retirements under the “profitability enhancement measures,” among other items.」
One-off expenses related to the profitability enhancement measures and site integration continued to be incurred, with ¥2,042 million in business structure improvement expenses and ¥98 million in losses on factory closures recorded. - FY2020-Q1MaterialisedAnnual report
「¥69 million was recorded in selling, general and administrative expenses as acquisition-related costs.」
The ¥69 million in acquisition-related costs associated with the acquisition of Eurofoil was actually incurred and recorded in selling, general and administrative expenses. - FY2019-Q3MaterialisedAnnual report
「Loss on factory closures 227 These relate to the integration of European production sites at a consolidated subsidiary in the “Medical Technology” segment.」
The company recorded a ¥227 million loss on factory closures associated with the integration of Medical Technology’s European production sites. Costs related to acquisition and growth-strategy integration remain ongoing. - FY2019-Q2MaterialisedAnnual report
「Loss on factory closures 105 Business structure improvement expenses 47 Business site relocation expenses 25」
The company recorded ¥105 million in losses on factory closures associated with the integration of its European production sites, ¥47 million in business structure improvement expenses associated with the restructuring of its Information and Communications business, and ¥25 million in business site relocation expenses. - FY2019-Q1MaterialisedAnnual report
「Extraordinary losses Loss on disposal and sale of fixed assets 159 Impairment loss on investment securities 184 Loss on factory closures 68 Business structure improvement expenses 47 Office relocation expenses 10」
During the quarter, the company recorded ¥68 million in losses on factory closures, ¥47 million in business structure improvement expenses and ¥10 million in office relocation expenses, among others, resulting in costs associated with restructuring and rationalization. - FY2018MaterialisedAnnual report
「In the consolidated fiscal year, product demand remained firm, particularly in the core contract manufacturing business, while sales of the new in-house branded ECG electrode, “Vermed Claraview,” progressed steadily. In addition, the consolidation of the results of 3 companies acquired during the fiscal year expanded the business scale. At the same time, one-off expenses, including acquisition-related costs and site integration costs, were incurred. As a result, consolidated net sales for the fiscal year were ¥22,351 million, up 22.8% year on year, EBITDA was ¥1,829 million, up 54.6%, and the segment loss (operating loss) was ¥60 million, compared with a segment loss (operating loss) of ¥500 million in the previous fiscal year.」
One-off expenses related to the acquisition and integration of 3 companies were incurred over the full year, and Medical Technology posted an operating loss of ¥60 million despite higher sales. - FY2018-Q2MaterialisedAnnual report
「Temporary costs were incurred in connection with acquisitions and their management integration, which were undertaken to enhance the added value of the business, including product design and development capabilities.」
Temporary costs associated with acquisitions and management integration in the Medical Technology business continued to be incurred, resulting in a segment operating loss of ¥24 million. - FY2017-Q3MaterialisedAnnual report
「These costs arose from the integration of production sites in the United States at a consolidated subsidiary in the Life Innovation segment.」
A plant closure loss of ¥54 million was recorded as an extraordinary loss in connection with the integration of Life Innovation's U.S. production sites, indicating that post-acquisition integration costs were actually incurred. - FY2017-Q2MaterialisedAnnual report
「During the cumulative first quarter of the current consolidated fiscal year, business scale expanded due in part to contributions from the medical device business, while upfront costs were incurred in the core Devices business in preparation for mass production of large orders. Overall, results progressed largely as expected.」
The company stated that upfront costs for mass production of large orders were actually incurred, indicating that the risk of bearing upfront costs continues to materialize. - FY2017MaterialisedAnnual report
「Plant closure loss ¥145 million These costs arose from the integration of production sites in the United States at a consolidated subsidiary in the Life Innovation segment.」
A plant closure loss of ¥145 million was recorded in connection with the integration of Life Innovation's U.S. production sites, indicating that post-acquisition integration costs continued to be incurred. - FY2017First statedAnnual report
「Results fell below expectations due to currency fluctuations, sluggish product demand in existing businesses, upfront costs associated with new orders, and the recognition of one-time acquisition-related costs, among other factors.」
The company stated that upfront costs associated with new orders and one-time acquisition-related costs were actually incurred, contributing to the downward pressure on results for the fiscal year, including a segment loss of ¥1,311 million in Life Innovation.